Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.300-2.400 for the period, compared to the consensus earnings per share estimate of 2.330. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q1 2026 guidance to 0.370-0.450 EPS.

Integra LifeSciences Price Performance

NASDAQ IART opened at $11.59 on Thursday. The company has a 50-day moving average price of $12.02 and a two-hundred day moving average price of $13.22. Integra LifeSciences has a 52 week low of $10.60 and a 52 week high of $24.86. The stock has a market cap of $902.75 million, a price-to-earnings ratio of -1.79 and a beta of 1.04. The company has a current ratio of 3.14, a quick ratio of 1.80 and a debt-to-equity ratio of 1.73.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.03. Integra LifeSciences had a positive return on equity of 14.06% and a negative net margin of 30.15%.During the same quarter in the prior year, the firm earned $0.97 earnings per share. The business’s revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

IART has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Truist Financial restated a “hold” rating and set a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Citigroup reduced their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $15.00.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter worth about $124,000. Invesco Ltd. lifted its holdings in shares of Integra LifeSciences by 0.9% in the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in shares of Integra LifeSciences in the fourth quarter worth $189,000. State of Tennessee Department of Treasury raised its position in Integra LifeSciences by 7.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the period. Finally, Wellington Management Group LLP raised its position in Integra LifeSciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company’s stock valued at $16,810,000 after buying an additional 32,192 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.